coadministered cagrilintide and semaglutide in adults with overweight or obesity Cagrilintide–Semaglutide Type 2 Diabetes cagrilintide trial In the REDEFINE

The therapeutic effect of semaglutide depends on its systemic absorption and action on GLP-1 receptors throughout the body, not on local tissue reactions at the injection site

Patients are selected based on clinical history, BMI, and risk profile

The key question isn't whether you want the medication

In experimental studies, augmentation of the actions of GLP-1 retards the growth and increases the stability of atherosclerotic plaques, thus minimizing the likelihood of plaque rupture [59, 60]

Wegovy is not covered for weight loss alone under Medicare

See FAQ section for BMI calculation and additional requirements